Tolerability of Combined Modality Therapy for Rectal Cancer in Elderly Patients Aged 75 Years and Older
Danielle N. Margalit(Harvard University), Theodore S. Hong(Massachusetts General Hospital), Wendy Kobayashi(Massachusetts General Hospital), David P. Ryan(East Carolina University), Lawrence S. Blaszkowsky(Brigham and Women's Hospital), Harvey J. Mamon(Brigham and Women's Hospital), Christopher G. Willett, Jeffrey W. Clark(Massachusetts General Hospital), Marek Ancukiewicz(Bridge University)
International Journal of Radiation Oncology*Biology*Physics
March 5, 2011
Cited by 73
Related Papers
Anaplastic Lymphoma Kinase Inhibition in Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2010|4.5k
Crizotinib in <i>ROS1</i>-Rearranged Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2014|2k
Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer
|Nature Medicine|2004|2k
<i>ROS1</i> Rearrangements Define a Unique Molecular Class of Lung Cancers
|Journal of Clinical Oncology|2012|1.6k